These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4921420)

  • 41. [Causes of early functional incompetence in allotransplanted organs].
    Vishnevskiĭ AA; Kolesnikov IS; Balliuzek FV; Portnoĭ VF; Kostin ED
    Eksp Khir Anesteziol; 1971; 16(1):3-8. PubMed ID: 4944577
    [No Abstract]   [Full Text] [Related]  

  • 42. Human renal allotransplants. Value of physical examination, biochemical, hematologic, and immunochemical testing.
    Murphy GP; Hesse VE; Reynoso GD; Moore RH; Cohen E; Kenny GM
    N Y State J Med; 1971 May; 71(9):956-60. PubMed ID: 4929520
    [No Abstract]   [Full Text] [Related]  

  • 43. Human renal allotransplants. Correlation of acute and chronic histologic alterations with endocrine function--a new syndrome?
    Murphy GP; Mirand EA; Gaeta JF; Weber HW
    N Y State J Med; 1971 Dec; 71(23):2743-6. PubMed ID: 4941134
    [No Abstract]   [Full Text] [Related]  

  • 44. The role of the HLA-D (D and DR) locus in the rejection of allografts.
    Dausset J; Fauchet R; Suet C; Busson M; Schmid M; Hors J
    Adv Nephrol Necker Hosp; 1980; 9():223-35. PubMed ID: 6773313
    [No Abstract]   [Full Text] [Related]  

  • 45. Allogeneic "rejection" of in situ rat kidney using humoral antibody.
    Straus A; Straus F; Roseman D
    Transplant Proc; 1971 Mar; 3(1):570-2. PubMed ID: 4937940
    [No Abstract]   [Full Text] [Related]  

  • 46. [Use of heterologous antilymphocyte serum in human renal transplants].
    Caralps A; Gil-Vernet JM; Brulles A; Andreu J
    Rev Clin Esp; 1971 Apr; 121(1):21-8. PubMed ID: 4935138
    [No Abstract]   [Full Text] [Related]  

  • 47. Are transplantation antigens stable constituents on human renal allografts?
    Häyry P; von Willebrand E; Ahonen J; Eklund B
    Proc Eur Dial Transplant Assoc; 1981; 18():367-74. PubMed ID: 6173879
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prolonged renal allograft survival: extracorporeal irradiation of blood.
    Chanana AD; Cronkite EP; Joel DD; Stevens JB
    Transplant Proc; 1971 Mar; 3(1):838-40. PubMed ID: 4937979
    [No Abstract]   [Full Text] [Related]  

  • 49. [Rejection in renal transplantation].
    de Lima JJ; Gerbase MB; Ianhez LE; Sabbaga E; Massola VC
    Rev Hosp Clin Fac Med Sao Paulo; 1971 Sep; 26(5):169-74. PubMed ID: 4941287
    [No Abstract]   [Full Text] [Related]  

  • 50. Prolongation of renal xenografts by the simultaneous sequestration of preformed antibody, inhibition of complement, coagulation and antibody synthesis.
    Moberg AW; Shons AR; Gewurz H; Mozes M; Najarian JS
    Transplant Proc; 1971 Mar; 3(1):538-41. PubMed ID: 4937935
    [No Abstract]   [Full Text] [Related]  

  • 51. The role of platelets in chronic rejection.
    Evans G; Mustard JF
    Laval Med; 1970 May; 41(5):Suppl:718-20. PubMed ID: 4928490
    [No Abstract]   [Full Text] [Related]  

  • 52. [Renal transplantation at the Maisonneuve-Rosemont Hospital: 10-year experience].
    Dandavino R; Barcelo R; Beaudry C; Cardinal J; Carrière S; Friborg J; Houde M; Girard R; Bastien E; Laplante L
    Union Med Can; 1981 Feb; 110(2):104-8. PubMed ID: 7010741
    [No Abstract]   [Full Text] [Related]  

  • 53. [Kidney transplantation. Immunologic problems].
    Scheiffarth F
    Munch Med Wochenschr; 1971 Jun; 113(23):903-5. PubMed ID: 4931697
    [No Abstract]   [Full Text] [Related]  

  • 54. [Current views on human organ and tissue transplantation. II. Practical aspects of kidney transplantation].
    Dóbiás G
    Orv Hetil; 1969 May; 110(21):1177-81. PubMed ID: 4893522
    [No Abstract]   [Full Text] [Related]  

  • 55. Characteristics of erythropoiesis following human renal homotransplantation.
    Jepson JH; De Leeuw NK; Gault MH; Dossetor JB; Manasc B
    Transplant Proc; 1971 Mar; 3(1):353-7. PubMed ID: 4937904
    [No Abstract]   [Full Text] [Related]  

  • 56. Controlled, double-blind trial of antiplatelet aggregating agents in vascular renal allograft rejection.
    Mathew TH; Hogan GP; Lewers DT; Bauer H; Maher JF; Schreiner GE
    Transplant Proc; 1971 Mar; 3(1):901-4. PubMed ID: 4937989
    [No Abstract]   [Full Text] [Related]  

  • 57. Histocompatibility concomitants of the clinical course of renal homografts.
    Hume DM; Lee HM; Pierce JC; Cobb GC
    Transplant Proc; 1971 Mar; 3(1):371-5. PubMed ID: 4937908
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluation of cadaver-donor renal transplantation.
    Sheil AG; Stewart JH; Johnson JR; May J; Charlesworth J; Kalowski S; Sharp AM; Bashir H
    Transplant Proc; 1971 Mar; 3(1):347-52. PubMed ID: 4937903
    [No Abstract]   [Full Text] [Related]  

  • 59. Hematopoietic origin of immunological target in enhancement of renal allografts.
    Guttmann RD; Lindquist RR
    Transplant Proc; 1971 Mar; 3(1):717-20. PubMed ID: 4937965
    [No Abstract]   [Full Text] [Related]  

  • 60. [Observations in rejections of kidney transplants].
    Siedek M
    Langenbecks Arch Chir; 1969; 325():714-9. PubMed ID: 4391978
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.